Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Equity Ratio (2022 - 2025)

Mereo BioPharma (MREO) has disclosed Equity Ratio for 4 consecutive years, with 0.89 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 11.65% to 0.89 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.89 through Dec 2025, up 11.65% year-over-year, with the annual reading at 0.89 for FY2025, 11.65% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.89 at Mereo BioPharma, up from 0.87 in the prior quarter.
  • The five-year high for Equity Ratio was 0.89 in Q4 2025, with the low at 0.82 in Q3 2024.
  • Average Equity Ratio over 4 years is 0.65, with a median of 0.81 recorded in 2024.
  • The sharpest move saw Equity Ratio grew 5.02% in 2024, then skyrocketed 206.36% in 2025.
  • Over 4 years, Equity Ratio stood at 0.66 in 2022, then rose by 14.45% to 0.76 in 2023, then rose by 5.02% to 0.8 in 2024, then increased by 11.65% to 0.89 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.89, 0.87, and 0.87 for Q4 2025, Q3 2025, and Q2 2025 respectively.